Clinical Trial Update: Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the effects of tregalizumab on allergen-induced airway responses and airway inflammation in patients with allergic asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma
• House Dust Mite Allergy

Drugs mentioned

• Tregalizumab (regalizumab)

Snippet

Sponsor: T-Balance Therapeutics GmbH | Conditions: Allergy to House Dust Mite, Allergic Asthma | Phase 2 | Status: COMPLETED